Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) represents a various
family of rare tumours. Surgery is the first choice in GEP-NENs patients with localized …

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in
endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary …

Peptide receptor radionuclide therapy (PRRT) is a widely accepted treatment for progressive
grade 1 and 2 (G1-2) gastroenteropancreatic neuroendocrine tumors (NET). There is …

Important progress has been made over the last decade in the classification, imaging, and
treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use …

Theranostics is the highly targeted molecular imaging and therapy of tumors. Targeted
peptide receptor radionuclide therapy has taken the lead in demonstrating the safety and …

Molecular targeted therapy of advanced neuroendocrine tumours (NETs) of the
gastroenteropancreatic (GEP) system currently encompasses approved therapy with the …

Objective Advanced pancreatic neuroendocrine tumors (pNETs) present a therapeutic
challenge with targeted therapies like Everolimus and 177 Lu-DOTATATE peptide receptor …

Pancreatic neuroendocrine neoplasms (PanNENs) are rare neoplasms with strong
heterogeneity that have experienced an increasing incidence rate in recent years. For …

In recent years, there have been important scientific advances in the biologic
characterization of neuroendocrine neoplasms and in their treatment. This review will …

Background Treatment options for metastatic gastroenteropancreatic neuroendocrine
tumors (NETs) have evolved in recent years. The somatostatin analogs octreotide and …